Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial

NCT04702516 is registered in ClinicalTrials.gov with Morten Frost as lead sponsor.

NCT NCT04702516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04702516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial
Lead sponsor
Morten Frost
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 24, 2021
Completion date
August 31, 2022
Enrollment
64 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteopenia